| P2093 | author name string | Satoshi Sawada | |
| | Noboru Tanigawa | |
| | Yumiko Kono | |
| | Shohei Kanno | |
| | Keita Utsunomiya | |
| P2860 | cites work | In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. | Q32046936 |
| | Apoptosis induced by high-LET radiations is not affected by cellular p53 gene status | Q33227562 |
| | Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin | Q33494135 |
| | Targeted therapies for non-small cell lung cancer | Q35012966 |
| | 99mTc-MIBI in the evaluation of breast cancer biology | Q35754746 |
| | Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense | Q36104162 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis | Q37395239 |
| | Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. | Q38165880 |
| | Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells | Q39610368 |
| | Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells | Q40018674 |
| | MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia | Q40352994 |
| | To use MIBI or not to use MIBI? That is the question when assessing tumour cells | Q40420581 |
| | Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line | Q40826027 |
| | Prognostic and predictive factors in breast cancer by immunohistochemical analysis. | Q40866567 |
| | Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells | Q41090169 |
| | Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients | Q41328786 |
| | 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. | Q41355510 |
| | In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. | Q41522468 |
| | Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging | Q43987709 |
| | Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model | Q44062508 |
| | Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. | Q53435815 |
| | The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. | Q53969193 |
| | Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. | Q54057212 |
| | Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration | Q68184512 |
| | PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein | Q77556599 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 11 | |
| P577 | publication date | 2015-03-17 | |
| P1433 | published in | EJNMMI Research | Q27723773 |
| P1476 | title | The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells | |
| P478 | volume | 5 | |